Companion Animal Arthritis Market Report 2026

Companion Animal Arthritis Market Overview

• Companion Animal Arthritis market size has reached to $4.07 billion in 2025 • Expected to grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Growing Trend Of Pet Adoption Boosts The Companion Animal Arthritis Market • Market Trend: Advancements In Monoclonal Antibody Therapy For Companion Animal Arthritis Treatment • North America was the largest region in 2025.

The key promising market opportunities in the companion animal arthritis market include: • Dogs (Segmentation By By Type) → Expected gain of $1.51 Billion • Cats (Segmentation By By Type) → Expected gain of $0.68 Billion • Other Types (Segmentation By By Type) → Expected gain of $0.33 Billion

What Is Covered Under Companion Animal Arthritis Market?

The companion animal arthritis refers to a condition involving inflammation of one or more joints in companion animals such as cats, dogs, and other exotic animals. Companion animal arthritis develops in the bones when the cartilage between joints becomes rougher and more worn, forcing the bone surfaces to rub against one another. The main type of companion animal arthritis are dogs, cats, and other types. The dogs companion animal arthritis is used for controlling pain and inflammation in dogs. Dogs are domesticated canines (Canis familiaris) that are usually kept as pets or trained for hunting, guarding individuals, or property. The companion animal arthritis indication are osteoarthritis and, other arthritis, that are treatment through medication, supplements and other treatment, which are sold and distributed through veterinary hospitals and clinics, retail pharmacies, online stores, and others.

What Is The Companion Animal Arthritis Market Growth Forecast?

The companion animal arthritis market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to rising pet humanization trends, increasing demand for advanced arthritis therapies, growth in senior pet population, expansion of online veterinary pharmacies, innovation in combination therapies and supplements. Major trends in the forecast period include rising prevalence of age-related arthritis in pets, increasing pet owner spending on chronic care, growing adoption of nutraceuticals and joint supplements, shift toward early diagnosis and preventive treatment, rising demand for long-term pain management solutions.

What Is The Driver Of The Companion Animal Arthritis Market?

Rising trend of pet adoption is expected to propel the growth of companion animal arthritis market. Pet adoption refers to the process of taking responsibility for a pet from a shelter or previous owner and providing it with care, food, and a safe home. Pet adoption is rising due to growing emotional awareness, as more people seek companionship and mental well-being through caring for animals. Companion animal arthritis treatments support pet adoption by giving potential owners confidence that age-related joint issues can be managed, making older pets easier to care for and more adoptable. For instance, in 2024, according to the Shelter Animals Count (SAC), a US-based nonprofit organization, dog adoption rates (percentage of adoptions relative to intakes) have increased 56% in 2023 to 57% in 2024. Therefore, the rising trend of pet adoption contributes significantly to the growth of the companion animal arthritis industry.

How Will The Drivers Impact Growth In The Global Companion Animal Arthritis Market?

• Growing Awareness Of Animal Health (High) – During the forecast period, the growing awareness of animal health is expected to become a key growth driver for the companion animal arthritis market by 2030. Pet owners are becoming increasingly proactive in recognizing mobility issues, joint discomfort, and age-related health conditions in companion animals. Educational initiatives from veterinary organizations and animal health companies are encouraging routine health assessments and earlier intervention for musculoskeletal disorders. This heightened awareness is supporting greater demand for arthritis diagnostics, monitoring services, and therapeutic solutions. The expanding focus on preventive and wellness-oriented pet care is further strengthening market development. • Advancements In Veterinary Pharmaceuticals (Medium) – During the forecast period, the advancements in veterinary pharmaceuticals are expected to emerge as a major factor driving the expansion of the companion animal arthritis market by 2030. Continuous innovation in animal health therapeutics is improving the effectiveness, safety, and convenience of arthritis management options. New formulations, extended-duration treatments, and targeted pain-relief solutions are helping veterinarians provide more personalized care for affected animals. Pharmaceutical companies are also increasing research efforts focused on chronic musculoskeletal conditions in pets. • Increasing Expenditure On Pet Healthcare (High) – During the forecast period, the increasing expenditure on pet healthcare is expected to act as a key growth catalyst for the companion animal arthritis market by 2030. Pet owners are allocating larger portions of household spending toward veterinary consultations, specialty treatments, rehabilitation services, and supportive care products. The growing humanization of pets is encouraging investment in comprehensive healthcare solutions that improve comfort, mobility, and overall well-being. Rising disposable incomes and broader access to premium veterinary services are also supporting sustained treatment adoption.

How Will The Restraints Impact Growth In The Global Companion Animal Arthritis Market?

• Limited Access To Veterinary Care (High) – During the forecast period, the limited access to veterinary care significantly restrains the companion animal arthritis market by reducing the rate of diagnosis and treatment adoption. In many rural and semi-urban regions, veterinary infrastructure is either inadequate or entirely absent, making it difficult for pet owners to seek timely medical attention for arthritis-related symptoms in animals. This delay often results in underdiagnosis or mismanagement of the condition, preventing the use of advanced therapies such as NSAIDs or monoclonal treatments. Additionally, a shortage of trained veterinarians and specialized diagnostic tools limits the ability to identify arthritis at early stages, when intervention is most effective. Financial constraints and long travel distances further discourage pet owners from pursuing consistent veterinary visits. As a result, demand for arthritis-related medications and services remains suppressed in these areas. This restricted accessibility ultimately slows market penetration and reduces overall revenue growth, particularly in emerging economies where companion animal ownership is increasing but healthcare access remains uneven. • Side Effects Of Medications (Medium) – During the forecast period, the potential side effects associated with arthritis medications act as a major restraint on market growth by creating hesitation among pet owners and veterinarians. Commonly used treatments such as NSAIDs can lead to adverse reactions including gastrointestinal issues, kidney dysfunction, and liver complications in animals, especially with prolonged use. Similarly, newer therapies like monoclonal antibodies, while promising, may still carry uncertainties regarding long-term safety and immune responses. These risks often result in cautious prescribing practices by veterinarians and reluctance among pet owners to initiate or continue treatment. In some cases, adverse effects necessitate discontinuation of therapy, reducing repeat purchases and long-term treatment adherence. Moreover, increased monitoring requirements for animals on such medications add to the overall cost and complexity of care. This safety concern limits the widespread adoption of pharmaceutical solutions and encourages some pet owners to seek alternative or non-medical management approaches, thereby constraining market expansion. • Lack Of Awareness In Developing Regions (High) – During the forecast period, the lack of awareness in developing regions is another critical factor restraining the companion animal arthritis market, as many pet owners are unable to recognize early signs or understand the seriousness of the condition. Symptoms such as reduced mobility, stiffness, or behavioral changes are often misinterpreted as normal aging rather than indicators of arthritis. This misconception delays diagnosis and reduces the likelihood of seeking veterinary care or purchasing appropriate treatments. Furthermore, limited educational outreach and insufficient dissemination of information about available therapies hinder market growth. In many developing countries, companion animal healthcare is not prioritized, and spending on pet wellness remains low compared to developed regions. Cultural attitudes and economic limitations further reduce the willingness to invest in long-term arthritis management. Consequently, the demand for arthritis-related products and services remains underdeveloped, restricting market expansion despite a growing population of companion animals.

Key Players In The Global Companion Animal Arthritis Market

Major companies operating in the companion animal arthritis market are Zoetis Inc., Merck Animal Health, Boehringer Ingelheim, Bayer Animal Health, Vetoquinol, Ceva Santé Animale, Dechra Pharmaceuticals, PetMed Express, Pet Health Solutions, VetriScience, Canine Arthritis Management, Integrative Pet Care, The Honest Kitchen, Vetri-Science Laboratories, Anivive Lifesciences, Nutramax Laboratories, Hill's Pet Nutrition, Royal Canin, Medivet, Virbac, Canna-Pet, Lintbells, Allivet, Petlab Co.

Global Companion Animal Arthritis Market Trends and Insights

Major companies in the companion animal arthritis market are increasingly focusing on technological innovations, such as advanced therapeutic products and supplements, to provide pets with effective pain relief and improved joint health, ensuring a higher quality of life for aging and arthritis-affected animals. Bonqat is a new medication developed for cats that helps reduce anxiety during stressful situations, such as travel or veterinary visits, without causing sedation. The product aims to calm cats, making it easier for them and their owners during trips or appointments. For instance, in April 2024, Zoetis Inc., a US-based company which manufactures medicine and vaccinations for pets and livestock, launched Bonqat (pregabalin oral solution) for alleviation of feline acute anxiety and fear associated with transportation and veterinary visits, which can be a barrier to routine care. The oral solution can be mixed with food or given directly to the cat, making it easier for pet owners to administer. The dosing is small (0.1 mL/kg), and a majority of cat owners have reported that administration is easy.

What Are Latest Mergers And Acquisitions In The Companion Animal Arthritis Market?

In January 2024, Ceva Santé Animale S.A., a France‑based provider of animal health solutions including preventive medicine (vaccines), pharmaceutical products for farm and companion animals, animal welfare products, and related equipment and services, acquired Scout Bio Inc. for an undisclosed amount. With this acquisition, Ceva aims to accelerate its global biotechnology efforts and expand its biotherapeutic capabilities by integrating Scout Bio’s pipeline of monoclonal antibodies and gene therapy innovations to address chronic diseases in pets, enhancing its position in cutting‑edge pet therapeutics. Scout Bio Inc. is a US‑based biotechnology company specializing in the development of novel biotherapeutic products for pets, including one‑time gene therapies and monoclonal antibody treatments designed to induce long‑term therapeutic protein expression for chronic animal health conditions.

What Defines the Companion Animal Arthritis Market?

The companion animal arthritis market includes revenues earned by entities by NSAIDs, monoclonal antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Companion Animal Arthritis Market Report 2026?

The companion animal arthritis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the companion animal arthritis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.